Sanofi announces EU approval of 6-in-1 pediatric vaccine
Hexyon/Hexacima is a ready-to-use, liquid, 6-in-1 vaccine that protects infants against Haemophilus influenza type b, poliomyelitis, hepatitis B, pertussis, tetanus and diphtheria. Sanofi will commercialize the vaccine under the brand name Hexyon in Western Europe and under the brand name Hexacima in Eastern European countries.
"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children," Olivier Charmeil, the president and CEO of Sanofi Pasteur, said. "It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases. We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."
By combining six vaccines, Hexyon/Hexacima reduces the number of injections, which can improve both comfort and compliance.
The EC decision was supported by the results of clinical studies involving approximately 5,000 infants that demonstrated the safety and robust immune response of Hexyon/Hexacima.